For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
✓500+ PubMed Citations✓Free To Use✓No Account Required
Back to Database
Growth Hormone Secretagogue

Tesamorelin Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity
Molecular Formula
C221H366N72O67S
Molecular Weight
5135.86 g/mol
CAS Number
218949-48-5

HIV-associated lipodystrophy research, Visceral-fat reduction, GH axis studies, NAFLD and body-composition research

Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat
Half-Life
26-38 minutes
Administration
Subcutaneous
Frequency
Once Daily, 90 Minutes After Last Meal, Before Bed

How It Works

  • HIV-associated lipodystrophy research
  • Visceral-fat reduction
  • GH axis studies
  • NAFLD and body-composition research

Dosing Structure

Dose
1 mg daily
Frequency
Once Daily, 90 Minutes After Last Meal, Before Bed
Notes
Standard: 1mg taken 90 minutes after last meal, before bed. Aggressive: 2mg taken 90 minutes after last meal, before bed. If on a GLP-1, consider taking dose first thing in the morning as GLP-1 delays fasted state by many hours. Inject: Abdomen (avoid navel ±2 inches), rotate sites. Break: 1-2 months.

Example Protocols

Dose: 1 mg daily
Frequency: Once Daily, 90 Minutes After Last Meal, Before Bed
Duration: 6-12 weeks
Off Period: Not listed
Calculate dosing →

Find Research Grade Tesamorelin

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon
View all recommended vendors →

Protocol Notes

•
Standard: 1mg taken 90 minutes after last meal, before bed.
•
Aggressive: 2mg taken 90 minutes after last meal, before bed.
•
If on a GLP-1, consider taking dose first thing in the morning as GLP-1 delays fasted state by many hours.
•
Inject: Abdomen (avoid navel ±2 inches), rotate sites.
•
Break: 1-2 months.

What Is Tesamorelin?

Tesamorelin is an FDA-approved synthetic GHRH analogue stabilized for improved pharmacokinetics. It is the only GHRH analogue with full regulatory approval in the United States - specifically for the reduction of excess abdominal visceral fat in HIV-infected adults with lipodystrophy (Egrifta). Researchers also study it for cognitive function, NASH (fatty liver), and as a comparison point for other GH secretagogues.

Research Observations - Not Medical Claims
  • ▸FDA-approved indication: Tesamorelin 2 mg/day SubQ reduced visceral adipose tissue (VAT) by 15–18% vs. placebo in HIV-associated lipodystrophy (PMID: 20357282) - the basis for FDA approval.
  • ▸Cognitive effects: MAST trial (PMID: 27749059) showed tesamorelin improved verbal memory and executive function in older adults at risk for Alzheimer's disease compared to placebo over 20 weeks.
  • ▸NASH reduction: Phase 2 data showed 3.6 mg/day tesamorelin reduced liver fat fraction by ~18% in non-HIV adults with NAFLD/NASH (PMID: 29505025).
  • ▸IGF-1 and GH: Tesamorelin raises mean GH and IGF-1 within the physiological range - avoiding supraphysiological spikes associated with direct GH injection.
  • ▸Benefit-risk profile: Published data shows favorable safety relative to GH injection - no significant changes in glucose homeostasis at approved doses despite elevated IGF-1.

Evidence Summary

Human Clinical Data AvailableFDA Approved - Egrifta (2 mg/day, HIV-associated lipodystrophy)
Evidence StrengthStrong
PreliminaryModerateStrong
Curated Citations3
Largest Study (n)412
Most Recent Study2024
Species Studied
HumanRat

Commonly Researched With

Ipamorelin
GHRH analogue (tesamorelin) + GHRP (ipamorelin) stack for GH pulse synergy - the same principle as CJC-1295/ipamorelin.
CJC-1295
Both GHRH analogues; tesamorelin has FDA approval giving it a better-characterized safety profile for reference.
NAD+
Combined in cognitive decline research protocols targeting mitochondrial function and GH-mediated brain repair.

Research & Studies

Loading citations…

Research Feedback

0 approved

For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.

Related Peptides

CJC without DAC (MOD-GRF)
Growth Hormone Secretagogue
CJC-1295 DAC
Growth Hormone Secretagogue
GHRP-2
Growth Hormone Secretagogue
GHRP-6
Growth Hormone Secretagogue